CORPORATE NEWS

# MASSIVEBIO

YEAR:2024 / ISSUE:06

**MASSIVE BIO:** CELEBRATING ACHIEVEMENTS AND CHARTING **A VISION FOR 2024**

**CLINICAL TRIALS** AS AN OPTION IN **CANCER TREATMENT**


**WHY DID MY CHILD** GET CANCER?

WHY ARE **CANCER CLINICAL TRIALS** IMPORTANT?

**MYELOFIBROSIS** TREATMENT OPTIONS

# Contents




**MASTHEAD**

**Publisher, CEO**
Selin Kurnaz, PhD.

**GM, CTO & COO**
Cagatay Culcuoglu

**Medical Director, CMO**
Arturo Loaiza-Bonilla, MD

**Chief Marketing Officer**
Erkan Terzi

**Chief Financial Officer**
Toygun Rauf Onaran

**Chief Product Officer**
Oz Huner

**Chief of Staff**
Aycan Emre

**Marketing Manager**
Ismet Kale

**Creative Marketing Manager**
Tugce Yenen

**Frequency: Biannually**
**Year: 2024**
**Issue: 06**


MASSIVEBIO

# A MESSAGE FROM SELIN

**As we embrace 2024, I am thrilled to reflect on Massive Bio's achievements and our vision ahead. Our 6th biannual magazine release marks another stride in our mission to revolutionize cancer care.**

In 2023, we significantly expanded our clinical trials to 78, showcasing our dedication to diverse and advanced treatment options. Our partnerships have flourished, with collaboration now extending to 29 pharmaceutical companies and involvement with 6 of the top 10 CROs, reinforcing our leadership in the industry.

**Our network has grown to include 275 patient advocacy groups, 2,850 referring physicians, and numerous hospitals and partners. This expansion enhances our ability to impact the healthcare sector significantly.**

For 2024, we set ambitious goals: enrolling 250,000 cancer patients, increasing our trial count to 200, expanding globally into 14 countries, and launching an innovative patient pre-screening product.

**Our vision is to profoundly impact cancer patients' lives and their families. We remain committed to advancing cancer care and support, fuelled by our inspiring journey and the promise of the future.**

A heartfelt thank you to our team, partners, and clients. Your support drives our success. Let's continue to make remarkable advancements in healthcare.

**Here's to a prosperous and joyful new year!**

Selin Kurnaz

PhD, Co-founder and CEO

# Massive Bio: Celebrating Achievements and Charting a Vision for 2024

**As we step into the new year, Massive Bio is delighted to share notable accomplishments that underscore our commitment to advancing cancer care and lay out ambitious goals for the future. We extend warm wishes for a Happy and Healthy New Year to all who have been part of our remarkable journey.**

## Recent Achievements:

**Increased Clinical Trials:** Achieving a significant milestone, we now have 78 ongoing clinical trials, reflecting substantial growth from 50 trials last year.

**Expanded Customer Base:** Our collaborative efforts have led to partnerships with 29 esteemed pharmaceutical companies, a testament to the trust placed in our innovative solutions.

**Pharma Commercial Product Success:** Revolutionizing patient identification, our solutions have made the process more effective, contributing to the success of pharmaceutical commercial products.

**Collaborations with Industry Leaders:** Proudly serving 6 of the top 10 Contract Research Organizations (CROs), our impact in the industry continues to expand.

**Extensive Network:** We've cultivated a robust network, collaborating with 275 patient advocacy groups, 2,850 referring physicians, 30 hospitals, and 30 strategic partners, thereby broadening our outreach and impact.

## Future Goals:

**Patient Enrollment:** Our vision for 2024 involves enrolling 250,000 cancer patients in our program, providing them with hope and access to advanced care options.

**Trial Expansion:** With the aim of furthering research and treatment capabilities, we are set to increase our trial count to an impressive 200.

**Customer Upgrade:** Focused on enhancing the quality of our partnerships, we aim to upgrade 75% of our customers to multi-trial programs.

**Global Expansion:** Massive Bio is gearing up to expand its footprint into 14 countries across Europe, LATAM, and Asia, including Argentina, Colombia, the Czech Republic, Denmark, Finland, Iceland, Japan, Mexico, Norway, Peru, South Korea, Sweden, Taiwan, and the United Kingdom.

**Innovative Product Launch:** Anticipate the unveiling of a groundbreaking new product that transforms patient pre-screening, setting a new standard in cancer care.

**Internal Investment:** Our strategic focus for 2024 involves significant internal investment, particularly in growing patient enrollment and expanding our impact.

## **Our Vision** for 2024:

In the forthcoming year, Massive Bio is steadfast in its dedication to expanding its reach and impact in the realm of cancer care. Our overarching goal is to extend a positive influence on the lives of more cancer patients and their loved ones. The commitment to making a meaningful difference in the landscape of cancer care and patient support is at the core of our vision for 2024.

The journey we have undertaken thus far has been nothing short of inspiring, marked by milestones and achievements that propel us forward. As we gaze upon the path that lies ahead, it is imbued with promise and the potential for transformative contributions to the field of healthcare.

We express our profound gratitude to our exceptional team, whose unwavering dedication and tireless efforts have been instrumental in our success. The synergy between our valued partners and clients has played a pivotal role in shaping our trajectory, and we acknowledge their integral role in the journey thus far.

Together, let us forge ahead and continue to make significant strides in healthcare innovation. Our collective mission is to revolutionize the landscape of cancer care, leaving an indelible mark on the industry. As we embark on the new year, we do so with the shared aspiration of fostering continued growth, amplifying our impact, and effecting positive change in the lives of those touched by cancer.

Here's to a year of not just sustained progress, but a year that stands as a testament to our commitment to making a lasting and positive impact on the healthcare ecosystem. May 2024 be a chapter in which our shared endeavors bear fruit, and the transformative power of our collective efforts resonates throughout the realm of cancer care.

# Massive Bio Announces Partnership with the Newly Launched Cancer Community Hub

## A Pioneering Digital Platform Set to Revolutionize Cancer Education and Support

Massive Bio partners with the newly launched Cancer Community Hub to amplify cancer education and support. This collaboration merges Massive Bio's AI expertise with the platform's resources, aiming to empower and inform the global cancer community.

Massive Bio, a global leader in AI-driven solutions for cancer treatment and clinical trial matching, is thrilled to announce its strategic support for the Cancer Community Hub. This groundbreaking online platform promises to reshape the landscape of cancer education and foster a supportive community for all those affected by the disease.
The Cancer Community Hub is poised to be a one-stop destination for those seeking detailed insights into various cancers. From Myelofibrosis and Multiple Myeloma to Non-small Cell Lung Cancer and beyond, the platform showcases physician articles, the latest research, educational content, and engaging infographics.

**Erkan Terzi**
Massive Bio CMO

Erkan Terzi, the driving force behind the Cancer Community Hub, expressed, "Our vision was to craft an all-encompassing platform for the cancer community. As we strive to stay updated with the latest in cancer research,

news, and trials, we realized the need for an online space where patients, caregivers, and medical professionals can connect, share, and draw strength from each other. Their journey shouldn't be a solitary one."

In light of the recent collaboration, Selin Kurnaz, Co-Founder of Massive Bio, remarked, "Spearheading innovations at Massive Bio has always been about patient empowerment. The Cancer Community Hub represents a monumental stride in that direction. It's more than just a platform; it's a beacon of hope, knowledge, and support for the global cancer community. We're immensely proud to align with such a transformative initiative."

**Key Features of the Cancer Community Hub include:**
**Forum:** An interactive space for discussions, post-sharing, topic creation, and community engagement.

**Resources:** Comprehensive access to magazines, newsletters, guidelines, and a specialized cancer dictionary.

**Clinical Trials & Research:** Updates and insights into ongoing trials and the latest research breakthroughs in oncology.

**Videos & News:** Diverse educational and news content to keep users informed and engaged. Drawing upon the strengths and expertise of Massive Bio, the collaboration aims to further enrich the offerings of the Cancer Community Hub. Massive Bio, with its stellar reputation in empowering cancer patients through cutting-edge AI solutions, will bring its expertise to the table to enhance user experience and ensure patients are provided with the best available resources.

"Massive Bio has always been at the forefront of patient-centric solutions in the field of oncology," remarked a representative from Massive Bio. "Supporting initiatives like the Cancer Community Hub aligns perfectly with our ethos. We believe in the power of informed decisions, community support, and technology to make a meaningful difference in the lives of cancer patients."

The Cancer Community Hub is now open for registrations, with a variety of membership options tailored to suit the needs of its diverse user base.

To discover more about the Cancer Community Hub, visit **www.cancercommunityhub.org.**

# Chemotherapy is not working?

## WE HAVE PROMISING NEW TARGETED THERAPIES FOR **HEAD AND NECK CANCER.**

**Start your journey today.**

# **Clinical Trials** as an Option in **Cancer Treatment**

Access to some of the newest and most innovative cancer treatments can be achieved through participation in clinical trials.

**Another path is through humanitarian early access programs for innovative drugs before they are licensed in our country. I will touch upon the benefits of early access in my next column. Cancer treatments are developing at a dizzying pace, and we are now at a point where numerous treatment options, different even from just a few years ago, have been developed.**

These studies have led to an explosion of new treatment options for cancer patients, many of which are still in the research phase. As physicians, how aware are we of these studies, which we may not be researching ourselves but could benefit our patients at certain stages?

## Close Monitoring:

**Patients participating in clinical trials are closely monitored by the research team, more so than other patients, in accordance with the requirements of the research protocol. Participants in these studies must undergo tests such as imaging and lab examinations at appropriate intervals, in addition to detailed face-to-face appointments. If a participant misses an appointment, efforts are made to reach them and obtain detailed information about their situation, ensuring that the visit is rescheduled as soon as possible.**

In our routine practice, how often can we offer such close and detailed follow-up to our patients not involved in research? Aren't there instances where appointments or tests for patients outside research are missed for one reason or another?

**Patients participating in clinical trials sometimes assume they will be treated like "guinea pigs," but the reality is quite the opposite. In clinical trials, the research team is close at hand to answer the patient's questions and alleviate their concerns.**

This is an often-overlooked advantage of participating in a clinical trial. The close monitoring of how participants respond to treatments in the study can provide a sense of security for many people, as it allows for a better understanding of the treatments.


## Low Cost:

Participants do not pay for anything, including the drugs used in clinical trials. Even travel expenses for mandatory visits are covered by the sponsor of the study.

**In some early-stage studies, participants may receive a minimal, ethical payment that does not encourage participation but compensates for time away from work.**

Clinical trials can provide access to treatments covered by the state at different clinical stages without restrictions. This can contribute to delaying the progression of the disease.

**A cancer patient in a clinical trial can receive expensive treatments funded by the sponsor's budget, reducing the state's health expenditure budget and even the current deficit caused by imported cancer drugs.**

Do we, as physicians, consider the financial benefits of clinical studies for the patient as much as we consider the cost of treatment? Patients should consult with insurance and healthcare providers to estimate costs before participating in a study. Many cancer centers have social workers and financial counselors to assist patients.

## The Chance to Help Others:

**Clinical trials offer an extraordinary opportunity for both doctors and patients to contribute to science and pave the way for future discoveries. I often hear from patients who want to help others with the same disease. There are many patient groups formed around this idea.**

Many vital treatments like immunotherapy, which we use today for our cancer patients, were approved for use by health authorities after being proven beneficial and safe in patients who participated in past research.

**Could we have developed these innovative treatments if we, as physicians, had not directed our patients whom we expected to medically benefit from these trials, or if patients had not volunteered to participate in clinical trials?**

We are aware that the faster we make decisions about clinical research and ensure that suitable patients participate in studies, the quicker we can facilitate the availability of innovative and cost-effective drugs.

## Which Cancer Patients Should We Include in Clinical Trials?

**It is a fact that clinical trials can be recommended for all patients, regardless of the type or stage of cancer.**

There are many promising treatment options that can be recommended while monitoring our patients. For some patients, a clinical trial might be the first step in treatment, while for others, it may be an option considered later.

**However, every cancer patient has the right to know about clinical trial options suitable for them. Can we deliver this natural right to our patients amidst our routine workload?**

## Should We Worry About Placebos?

Often, patients in clinical trials receive one of two treatments: either the trial treatment or a placebo. It is important to understand that the placebo arm of a clinical study should be as good as or better than the current standard treatment.

**Being in the placebo arm does not mean that the patient will not receive any treatment. In the worst case, the patient receives the same standard, effective treatment as patients not participating in the clinical trial.**

Have you ever decided not to recommend a patient for a clinical trial due to concerns they might end up in the placebo group?

**Patients are their own best advocates, and I believe they should always be encouraged to explore clinical trial options that may be suitable for them. One day, ClinicalTrials.gov might be a source of hope for you or a loved one. I wish you all days filled with health and science, away from illness.**

**Serdar Altinel, MD. PhD.**
*Vice President of Clinical Operations at Massive Bio*


THERE'S
ALWAYS
HOPE!
We will help you to find treatment options if you have been diagnosed with cancer and have a specific mutation.
Find
a Clinical Trial
Near You

Because life matters most.

further®

# Further Group Collaborates with Massive Bio,

## Integrating Health Insurance Solutions to Boost Access Cancer Clinical Trials Globally

**Further Group, a leading global provider of turnkey solutions for the insurance industry with the objective of breaking down barriers to access cutting-edge medical treatments, is thrilled to announce a transformative partnership with Massive Bio, a pioneer in leveraging artificial intelligence to enhance equitable access and precision targeting for cancer patients.**

**This strategic alliance will impact the lives of patients by streamlining access to clinical trials and advancing data-driven cancer treatments.**

### Partnership Scope:

In this collaborative initiative, Massive Bio will work closely with Further Group to identify eligible patients who can benefit from participation in clinical trials. With the integration of health insurance solutions, patients will have enhanced access to these trials. Massive Bio will offer indispensable support in streamlining the triage process and ensuring smooth patient enrolment. By leveraging their AI-driven expertise, Massive Bio will enhance Further Group's ability to connect patients with the most promising treatment options, ensuring they receive the best care available.

### Commentary from Ana Antunes, Head of Global Operations, Further Group:

"We are tremendously excited about our partnership with Massive Bio. This collaboration signifies a giant leap toward our shared goal of making innovative and life-saving cancer treatments accessible to patients worldwide. By combining Further Group's extensive global reach and Massive Bio's cutting-edge artificial intelligence, we are confident that this alliance will revolutionise cancer care by offering more opportunities and hope to patients and their families. Together, we are breaking down barriers and transforming the landscape of cancer treatment."

## Commentary from Toygun Onaran, Chief Financial Officer, Massive Bio:

“Our partnership with Further Group is a significant milestone in our mission to make cancer care accessible worldwide.

We are excited to leverage our AI technology to identify optimal clinical trial options, ensuring personalized treatments for patients globally.

This collaboration strengthens our commitment to advancing cancer care, offering renewed hope to patients and families, and transforming the landscape of oncology.”

This partnership represents a significant step forward in the fight against cancer, offering hope and advanced treatment options to patients who need it the most.

Further Group and Massive Bio are committed to continuing their efforts to improve the lives of individuals battling cancer and ensuring a brighter, healthier future for all.

# **Massive Bio Celebrates Milestones:** A Visionary Leader and Global Partnerships in 2023

As we reflect on the incredible achievements of 2023, Massive Bio stands out as a beacon of innovation and dedication in the biotech industry. Our co-founder, Selin Kurnaz, has been rightfully recognized as one of the "12 Women-Led Biotech Companies That Crushed it in 2023" by Biotech Metropolitan Women. This accolade is a testament to her relentless pursuit of excellence and her commitment to revolutionizing cancer care.

**Massive Bio's journey in 2023 was marked by significant advancements and strategic partnerships, aimed at improving clinical trial access and offering state-of-the-art treatments to cancer patients worldwide.**

Under Selin's visionary leadership, Massive Bio has become synonymous with breaking down barriers in healthcare, ensuring that every individual, regardless of location or financial status, has access to cutting-edge therapies.

**A pivotal innovation in 2023 was the introduction of our Chat GPT-4 AI chatbots, AskFiona AI and DrArturo AI, at ASCO 2023. These AI-driven tools have redefined patient and provider engagement, offering unparalleled access to clinical trials and personalized cancer treatments.**

## Our strategic collaborations have been instrumental in enhancing our service offerings:

- **The Oncology Institute:** Revolutionizing cancer treatment through the integration of advanced AI technology and a nationwide clinical trial network.
- **Precision Cancer Consortium:** Advancing precision oncology and optimizing clinical trial matching.
- **CureMatch:** Combining precision medicine with AI-driven clinical trial matching.
- **Health in Code:** Offering advanced genomic testing for personalized oncology.
- **Neogenomics:** Improving drug discovery phases and clinical trial placement.
- **Asklepieia:** Accelerating clinical trial processes in Greece.
- **Further Group:** Streamlining triage processes for serious illness solutions in the insurance industry.

As we look towards 2024, Massive Bio is poised for continued growth and innovation.

We are committed to advancing AI-driven clinical trial matching, expanding personalized oncology solutions, and forging global collaborations.

**Our goal remains steadfast:** to transform the landscape of cancer treatment and bring hope to patients and their families worldwide.

With Selin Kurnaz at the helm, recognized for her exceptional leadership and contribution to the biotech industry, Massive Bio is not just envisioning a brighter future in healthcare – we are actively creating it.

# Massive Bio's Co-Founder Dr. Arturo Loaiza-Bonilla Participates in Europe's Leading Health Tech Event

The Health Tech Forward conference, held on November 28-29, 2023 in Warsaw, marked an important gathering in the field of digital health and wellness. Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer of Massive Bio, was among the key participants, representing his company and contributing to critical discussions at the event.

**Europe's premier event for health tech innovation, Health Tech Forward 2023, convened digital health entrepreneurs, investors, providers, payers, employee benefits leaders, consumer tech and wellness brands, and tech giants. The event was noted for its dedication to delivering quality content and offering significant networking opportunities.**

Over two days, the conference featured empowering keynote speeches, dynamic panel discussions, and interactive fireside chats, focusing on cutting-edge technologies in health and wellness.

**A key feature of the conference was a panel discussion with Dr. Arturo Loaiza-Bonilla of Massive Bio, focusing on the value in healthcare.**

The discussion delved into enhancing patient outcomes and managing healthcare costs through data and digital technologies, highlighting Dr. Loaiza-Bonilla's expertise in integrating clinical practice with technological innovation.

**Dr. Arturo Loaiza-Bonilla's input at the Health Tech Forward 2023 conference, based on his experience, underscored Massive Bio's influence in healthcare technology. The event underscored the company's dedication to advancing health tech.**

# **Massive Bio and Health in Code Collaborate** to Enhance Personalized Oncology Treatment Through Advanced Genomic Testing

Leading personalized medicine providers, Massive Bio and Health in Code, announced today a groundbreaking collaboration. This partnership is set to redefine the landscape of cancer treatment by combining Massive Bio's Artificial Intelligence (AI) capabilities with Health in Code's advanced genomic testing.

**The collaboration focuses on delivering personalized medicine to cancer patients, which is essential in the present era where precision oncology is becoming paramount. By incorporating biomarker testing and genomic data into clinical decision-making, both organizations aim to provide more accurate and individualized treatments for cancer patients.**

The core of the collaboration lies in the goal to increase patient access to clinical trials and precision oncology. Integrating Health in Code's state-of-the-art cancer genetic knowledge and testing capabilities with Massive Bio's AI-driven prescreening tools are expected toimprove health outcomes and significantly reduce costs. This union is promising, especially for patients in Spain, where Health in Code has a significant presence.

**The partnership between Massive Bio and Health in Code is not merely transactional but it is built on shared values and a commitment to groundbreaking research. Both organizations believe that this collaboration will set a new standard in cancer care, emphasizing a data-driven and patient-centric approach.**

They are planning a series of webinars and patient engagement events in the upcoming months to educate the public about the benefits of biomarker detection for personalized medicine and the breakthroughs this collaboration aims to achieve. This commitment to patient education and advocacy further underscores their collective dedication to transforming the future of oncology.

**"Health in Code Group has always focused its efforts on making available to clinicians state-of-the-art technology and all the knowledge necessary for the implementation of genetic biomarkers in cancer patients management. By collaborating with Massive Bio, we will facilitate oncology patients access to clinical trials, enabling them to benefit from precision medicine", remarked Inés Calabria, PhD, Head of Oncology at Health in Code.**

# Clinical trial options are available near you for treating.

## ADVANCED MANTLE CELL LYMPHOMA.

# **Massive Bio Partners with Vithas** to Elevate Spain's Cancer Trial Opportunities

The collaboration will harness the power of Massive Bio's AI technology to optimize clinical trial matches, aiming to revolutionize cancer care for Spanish patients.

**Massive Bio, and Vithas Hospital Group, one of Spain's leading health networks, announced an unprecedented partnership aimed at redefining cancer patient care by providing streamlined access to clinical trials within Spain. The collaboration integrates Massive Bio's advanced artificial intelligence (AI) platform to enhance the prescreening process and identification of suitable clinical trials for patients, ensuring they receive cutting-edge treatment options tailored to their needs.**

Massive Bio's technology, designed to empower cancer patients, uses artificial intelligence to ensure precision in clinical trial matching, drug matching, and drug development. The technology will now act as a beacon for Vithas Hospital Group's medical professionals, guiding them through this maze with increased clarity and efficiency.

**The partnership will see Massive Bio providing invaluable support to the medical professionals at Vithas Hospital Group. From the prescreening process to delivering intricate information on clinical trials, Massive Bio is set to bridge the gap between the hospital's medical professionals and principal investigators at active trial sites.**

This symbiotic relationship will also allow Massive Bio to oversee and provide ongoing support during the patient referral process to clinical trials.

**Utilizing advanced AI technology, both organizations prioritize patient care and medical advancement. As global health evolves, this collaboration highlights technology's potential to drive significant change, ensuring optimal recovery** chances and better patient quality of life.

# **Myelofibrosis**
# Treatment Options

**Each patient is affected by MF in different ways. Your doctor can arrange your therapy based on your age, blood cell counts, amounts of immature blood cells called blasts, and symptoms including anemia or severe weight loss.**

## TREATMENT FOR ANEMIA

If myelofibrosis is causing severe anemia, you may consider treatments, such as:

### Blood transfusions:

If the patient has severe anemia, periodic blood transfusions can increase your red blood cell count and ease anemia symptoms, such as fatigue and weakness. Sometimes, medications can help improve anemia.

### Androgen therapy:

Taking a synthetic version of the male hormone androgen may promote red blood cell production and improve severe anemia in some patients. Androgen therapy does have risks, including liver damage and masculinizing effects in female patients.

### Thalidomide and related medications:

Thalidomide (Thalomid) and the related drug lenalidomide (Revlimid) may help improve blood cell counts and may also relieve an enlarged spleen. These drugs may be combined with steroid medications. Thalidomide and related drugs carry a risk of severe birth defects and require special precautions.



### Interferon alfa-2a:

Your doctor might try injections of these man-made versions of cells your body creates to fight tumors. It could cause depression or worsen problems like diabetes, immune disorders, and thyroid conditions.

## TREATMENT FOR AN ENLARGED SPLEEN

If an enlarged spleen is causing complications, your doctor may recommend treatment. Your options may include:

### Targeted drug therapy:

Targeted drug treatments focus on specific abnormalities present within cancer cells. Targeted treatments for myelofibrosis focus on cells with the JAK2 gene mutation. These treatments are used to reduce symptoms of an enlarged spleen.

### Chemotherapy:

Chemotherapy uses powerful drugs to kill cancer cells. Chemotherapy drugs may reduce the size of an enlarged spleen and relieve related symptoms, such as pain.

### Surgical removal of the spleen (splenectomy):

If the spleen becomes so large that it causes pain and harmful complications — and if the patient does not respond to other forms of therapy — they may benefit from having the spleen surgically removed. Risks include infection, excessive bleeding, and blood clot formation leading to stroke or pulmonary embolism. After the procedure, some patients experience liver enlargement and an abnormal increase in platelet count.

### Radiation therapy:

Radiation uses high-powered beams, such as X-rays and protons, to kill cancer cells. Radiation therapy can help reduce the size of the spleen when surgical removal isn't an option.

## TREATING MUTATED GENES

In a laboratory, doctors will analyze your blood or bone marrow cells for gene mutations, such as JAK2, CALR, and MPL. Your doctor uses the information from these tests to determine your prognosis and your treatment options.

## BONE MARROW TRANSPLANT

A bone marrow transplant, also known as a stem cell transplant, is a surgery that uses healthy blood stem cells to replace the damaged bone marrow. The method for myelofibrosis uses stem cells from a donor (allogeneic stem cell transplant).

Although this treatment has the potential to cure myelofibrosis, it comes with a high risk of life-threatening adverse effects, including the possibility that the new stem cells would react against the healthy tissues present in the patient's body.

Many patients with myelofibrosis do not qualify for this treatment because of age, stability of the disease, or other health problems.

Prior to a bone marrow transplant, the patient receives chemotherapy or radiation therapy to destroy the diseased bone marrow. Then receives infusions of stem cells from a compatible donor.

## MYELOFIBROSIS CLINICAL TRIALS

Massive Bio specializes in finding advanced clinical treatments for every type of myeloproliferative neoplasms (MPNs).

If you've been diagnosed with any of the following MPN subtypes, we're here to help. If you don't know which type of MPN, you have, that's okay.

**You can request a free consultation from our experts. Additional testing can help you determine your exact diagnosis.**

- **Primary Myelofibrosis (also known as chronic idiopathic myelofibrosis)**
- **Chronic Myelogenous Leukemia**
- **Essential Thrombocythemia (ET)**
- **Chronic Neutrophilic Leukemia**
- **Chronic Eosinophilic Leukemia**
- **Polycythemia Vera Treatment (PV)**
- **Multiple Myeloma Treatment**

# Myelofibrosis Clinical Trial!

- Myelofibrosis diagnosis.
- Have been taking Jakafi (Ruxolitinib) for 6 months?
- Have an enlarged spleen and severe symptoms?

**You might be eligible!**



# Why Did My Child Get Cancer?

A cancer diagnosis is shocking and upsetting for anyone, but learning that a child has cancer seems especially cruel and unfair. It's entirely natural for a parent to wonder: Why did my child get cancer?

**The reason that any child develops cancer is unknown, but it's clear that there are some differences between kids and adults with regard to what triggers a malignant tumor to form.**

In adults, many forms of cancer are linked to lifestyle choices, such as smoking tobacco, drinking alcohol, and consuming a poor diet. But it takes years for the effects of these habits to produce changes in cells that make them grow uncontrollably and cause cancer, so it's unlikely that lifestyle choices and other behaviors are a major cause of cancer in children.

**Instead, scientists believe that most cases of childhood cancer are caused by gene mutations. Genes carry the instructions for creating and sustaining the human body and its characteristics. Think of a mutation as an error in the instructions. Some gene mutations are harmless, but others can increase the risk for cancer and other diseases.**
A small number of cancer-causing gene mutations in children (about 6 to 8 percent) are inherited in the genes a child receives from a parent. But the majority of cancer-causing gene mutations in children seem to occur randomly when a cell makes a copy of itself.

**However, there is some evidence that certain environmental exposures (such as to some forms of radiation) may also cause these genetic alterations (known as acquired mutations) in children.**

## COMMON SYMPTOMS OF CHILDHOOD CANCERS

Each type of cancer affects the body in different ways, so the symptoms vary from one form to another.

**If your child develops any of the following symptoms and they persist, don't be alarmed, since they can be caused by many different medical conditions. However, be sure to have your child examined by a physician, soon.**

- **Fever that doesn't go away**
- **Nausea, with or without vomiting**
- **Easy bruising**
- **Unexplained lump or swelling, especially in the neck, abdomen, chest, pel vis, or armpits**
- **Lack of energy**
- **Pale skin**
- **Headaches**
- **A persistent pain**
- **Vision changes**
- **Whiteness behind the pupil**
- **Unexplained weight loss**
- **Unexplained limping**

## PRESERVING A CHILD'S FERTILITY

Some cancer treatments may cause irreversible damage to sex organs or require the surgical removal of tissues needed in female patients to become pregnant. Still other therapies may alter hormone levels in a way that affects fertility later in life.

Talk to your child's doctor about whether any strategies or pre-treatment procedures are necessary to protect the child's fertility.

**Some examples include:**

- Shielding the ovaries (for girls) and testicles) for boys during radiation treatment.

- Obtaining and freezing eggs for a girl who has gone through puberty.

- Sperm banking for boys who have gone through puberty.

# HOW GENETICS IMPACT **PEDIATRIC CANCER** CLINICAL TRIALS


**PODCAST**
From a channel with
a health professional
licensed in the US

# IF YOUR CHILD HAS BEEN FOUND OUT WITH **CHILDHOOD CANCER,**

you're already on the path to potentially innovative treatments.

# **Massive Bio and Fundación ECO Announce** Strategic Partnership to Enhance Cancer Patient Care in Spain

Massive Bio, a global leader in the application of artificial intelligence to enhance cancer clinical trial selection options, and Fundación ECO, a renowned Spanish organization dedicated to the advancement of oncological care, proudly announce their strategic collaboration. This partnership aims to improve patient experience and access to clinical trials through precision medicine in Spain.

**The collaboration underscores the shared commitment of both organizations to elevating the quality of life for cancer patients and enhancing disease management. With the prestigious backing of Fundación ECO, Massive Bio will join hands with leading oncologists in Spain, providing pivotal support in the ongoing battle against cancer.**

“This partnership is established to create synergies and take advantage of the possibilities that AI offers in the approach to cancer. This collaboration will undoubtedly allow us to improve the experience of oncology patients and increase access to clinical trials, thanks to the application of new approaches based on the study and exploitation of patient data”, said the president of the ECO Foundation, Dr. Jesús García-Foncillas.

**Selin Kurnaz PhD, Co-Founder and CEO of Massive Bio, remarked, "Joining forces with Fundación ECO aligns perfectly with our collective goal of harnessing technology, data and services to aid cancer patients. This alliance marks a pivotal step in our worldwide efforts to speed up access to clinical trials to patients regardless of their location and/or financial stability."**

The synergy between Massive Bio and Fundación ECO is expected to yield a series of innovative initiatives in the coming months. This partnership will offer unique solutions and tools for patients, medical professionals, and researchers. The future endeavors will focus on patient-centric approaches, ensuring evidence based and comprehensive care for individuals at every stage of their cancer journey.

# MASSIVE BIO EARNS **"Licensed from a Health Professional"** Tag in YouTube Health Initiative

**YouTube recognized the global thirst for reliable health content and introduced the "YouTube Health" tag to empower content creators in the health field. Their mission statement was clear: "We are committed to ensuring that everyone can learn from leading medical experts regardless of who they are or where they live.**
**To combat the societal threat of medical misinformation, we're working to fill the health information space with digestible, compelling, and emotionally supportive health videos."**

One notable contributor to this initiative is Massive Bio, a channel dedicated to producing content related to cancer diseases, raising awareness about cancer, and shedding light on clinical trials. For some time, they have been actively creating informative video content about the disease and clinical trials, aiming to reach a broader audience of YouTube viewers in search of accurate information.

Massive Bio's dedication to delivering credible health content led them to join this program, and their channel received the prestigious "Licensed from a health professional" tag from YouTube. This recognition validates the authenticity of their content and enhances its visibility in standard YouTube searches under the category "Health sources."

Furthermore, YouTube formally acknowledged Massive Bio's expertise in sharing information about cancer and related clinical trials. The evaluation process for this qualification involved a thorough review by reputable organizations such as the National Academy of Medicine, the American Public Health Association, and the World Health Organization. These endorsements underscore Massive Bio's unwavering commitment to providing trustworthy and valuable health information, aligning with the United Nations' focus on well-being and setting new standards in health communication across social media platforms.

This achievement exemplifies the power of collaborative efforts between online platforms and health professionals in disseminating accurate health information to a global audience. It marks a significant step forward in combating medical misinformation and empowering individuals to make informed health decisions.

# Gene Mutations In NSCLC

**Genes hold the instructions for making proteins needed for the healthy functioning and replication of every cell in your body.**

**Mutations (also called variants) can occur in a gene and lead a cell to function abnormally. As this abnormal cell replicates, or divides, it passes mutations onto new cells. When these abnormal cells grow and spread uncontrollably, cancer can develop. Lung cancer patients who test positive for certain gene mutations often have a more aggressive and faster-spreading form of the disease than patients who don't have those variants.**

**There are two basic types of lung cancer, known as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is by far the more common, representing 86 percent of all lung cancer cases. However, gene mutations can occur in both types of lung cancer.**

## TYPES OF GENE MUTATIONS IN NSCLC

There are two main types of mutations that can occur in genes, germline and somatic.

**Germline mutations are hereditary, meaning that a person has no influence over whether they occur. In contrast, somatic mutations happen during one's lifetime and can be caused by external factors, such as exposure to chemicals or toxins, as well as lifestyle**

**In NSCLC, mutations in the KRAS and BRAF genes are associated with smoking, while ROS1 and ALK gene mutations are seen more often in younger cancer patients with no history of smoking.**

Several other gene mutations have also been linked to NSCLC. Drugs designed to target these mutations have been developed—some are approved by the U.S. Food and Drug Administration (FDA), while others are being investigated in clinical trials.

## EGFR

Epidermal growth factor receptor (EGFR) is a protein present on the surface of cells that helps them grow and divide.

**Mutations in the EGFR gene, which produces this protein, cause it to remain turned "on" all the time and overproduce cells, leading to tumor growth. EGFR gene mutations are linked to pancreatic cancer, head and neck cancers, and lung cancer. About 23 percent of NSCLC tumors have the EGFR mutation present.**

Thanks to drug development in clinical trials, the FDA has approved medications such as gefitinib (Iressa) and erlotinib (Tarceva) that interfere with tumor growth by binding to the EFGR-1 receptor to prevent it from working, leading to the death of cancer cells.

## TP53

**The TP53 gene is responsible for producing a protein called tumor protein 53, whose role is to stop tumors from forming by repairing damaged DNA and preventing cells with mutations that could cause cancer from dividing.**

TP53 gene mutations have been linked to many different types of cancer, including NSCLC. The. TP53 gene mutation is the most common one associated with lung cancer and is present in about half of all NSCLC cases. There are currently no approved targeted therapies for TP53-positive NSCLC.

## KRAS

**KRAS is a gene that makes proteins involved in cell signaling pathways that facilitate the growth and maturation of cells.**

Mutations in KRAS and similar genes (called oncogenes) can cause normal cells to become malignant and form tumors. KRAS mutations occur in several cancers, including colorectal cancer, pancreatic cancer, and lung cancer.

**Almost a third of patients with NSCLC have a KRAS gene mutation present, which is particularly common in smokers, who often have a poor prognosis. However, patients who test positive for this gene mutation may be candidates for therapies that target KRAS, such as FDA-approved sotorasib (Lumakras) and drugs being studied in clinical trials.**

## MET

The MET gene makes a protein that sends signals within cells that play an important role in their growth and survival. Mutated forms of the MET gene can cause abnormal cells to grow uncontrollably and spread throughout the body. MET gene mutations are found in patients with liver, head and neck, and lung cancers.

**A particular error in MET, called exon 14 skipping, has the most impact on lung cancer therapy. Normally, when the MET protein is no longer needed, a protein called CBL helps break it down so it can be removed from the cell. However, when there is a mistake in a section of MET's code that causes a segment known as exon 14 to be missing, CBL can't interact with the MET protein. As a result, the MET protein remains longer and sends growth signals that can promote cancer.**

# DISCOVER YOUR POTENTIAL FOR HEALING AND PROGRESS.

**EMBRACE INNOVATION IN NSCLC THROUGH CLINICAL TRIALS.**

About 5 percent of lung cancer patients have MET exon 14 skipping present and are often treated with drugs such as capmatinib (Tabrecta) and tepotinib (Tepmetko).

## ALK

**The ALK (anaplastic lymphoma kinase) gene plays a role in human development, specifically in the formation of the gut and nervous system. Normally, this gene turns "off" while a fetus is still in the womb. However, ALK can be turned back "on" during a person's lifespan and fuse with other genes, especially one called EML4. ALK gene fusion can cause cancer.**

ALK was originally discovered in cases of lymphoma, but most tumors that are ALK-positive cancer are NSCLC. Each year, roughly 72,000 patients around the world are diagnosed with ALK-positive lung cancer, which is the cancer type with the highest occurrence of ALK fusions and mutations, followed by lymphoma. ALK-positive NSCLC is often treated with lorlatinib(Lorbrena).

## ROS1

**Like many other genes linked to cancer, ROS1 carries the instructions for making a protein that is involved in signaling within cells that promotes growth. And as with the ALK gene, ROS1 can fuse with other genes and promote cancer. ROS1 fusions are linked to several malignancies, including NSCLC.**

In lung cancer, ROS1 most commonly fuses with the CD74 gene. Cancer patients with these fusions are said to be ROS1-positive. Roughly 1 to 2 percent of NSCLC patients have ROS1 fusions (also called rearrangements) and are often treated with crizotinib (Xalkori) or entrectinib (Rozlytrek).

## BRAF

**The BRAF gene carries the code for making a protein that helps regulate many functions, including how a cell grows, develops specialized roles, moves about, and self-destructs when it's no longer needed.**

Many forms of cancer have been linked to BRAF mutations. That includes about 3 to 4 percent of patients with NSCLC. BRAF-positive NSCLC is typically treated with one of two FDA approved drugs, dabrafenib (Tafinlar) and trametinib (Mekinist).

## HOW ARE GENE MUTATIONS DIAGNOSED IN NSCLC?

**To determine if your lung cancer is positive for any of the above biomarkers, a doctor will use one or more of the following tests:**

**FISH analysis:** examines tissue under a microscope to detect changes in chromosomes

**Immunohistochemistry:** looks for specific proteins in abnormal cells under a microscope

**Next-generation sequencing (or comprehensive biomarker testing):** tissue from a patient's tumor (obtained from a biopsy) is placed in a machine that scans many genes for mutations at one time

Testing positive for a gene mutation associated with NSCLC may mean you're a candidate for approved targeted therapies or treatments under investigation in clinical trials.

Massive Bio and The Oncology Institute (TOI)

# Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care.

This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.

**Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services.**

Cristina Green, Vice President of Clinical Research, shared her enthusiasm for this partnership, stating, "This collaboration with Massive Bio complements our ability to connect patients with advanced cancer therapies and cutting-edge clinical trials. By leveraging AI-driven precision medicine, we are confident that this partnership will accelerate breakthroughs in cancer research and deliver life-changing treatment options to our patients."

**"We are incredibly excited about joining forces with The Oncology Institute," said Selin Kurnaz, Ph.D., CEO of Massive Bio. "This partnership will not only revolutionize cancer care but will also empower patients**



**with access to the most advanced precision medicine available. Our combined expertise will open new doors for patients, connecting them to potentially life-saving treatments and groundbreaking clinical trials."**

Furthermore, this collaboration will expand the scope of cancer research through Massive Bio's recent ChatGPT-powered chatbots for oncology research release during ASCO 2023. Dr. Arturo Loaiza-Bonilla, renowned oncologist and a key figure in the development of the chatbot technology, stated, "We are proud to be part of this innovative partnership between Massive Bio and TOI. The integration of AI-driven chatbots with clinical decision-support tools will revolutionize the way researchers access and analyze oncology data, enabling more efficient and impactful research initiatives, and will bolster this newly forged alliance to the betterment of all cancer patients."
**The alliance between Massive Bio and TOI represents a paradigm shift in cancer care, combining the power of advanced AI technology, personalized therapy, and an extended network of research collaborations. Together, these industry leaders are poised to reshape the future of oncology and bring new hope to patients and their families.**

## About TOI

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 700 teammates in over 60 clinic locations and growing, TOI is changing oncology for the better. For more information visit **www.theoncologyinstitute.com.**

# PARTICIPATE IN A CLINICAL TRIAL

## IS IT SAFE FOR ME TO PARTICIPATE IN A CLINICAL TRIAL?

The FDA and other regulators require developers of new drugs to take extensive precautions to ensure the safety of people who volunteer to participate in clinical trials.

**Testing of experimental therapies begins in a laboratory, often using human cells, to see how they respond to a drug. The drug will also be given to laboratory animals to find out how it affects them.**

Researchers must present data demonstrating that a new therapy appears to be safe to the FDA before the agency grants approval for clinical trials to begin.

## DOES IT COST MONEY TO PARTICIPATE IN A CLINICAL TRIAL?

In most cases, a patient's health insurance plan covers the routine costs of treatment in a clinical trial.

**If the participant lives a long distance from the site of the clinical trial, he or she may incur significant travel and lodging expenses. However, in many cases the sponsor of a clinical trial will reimburse participants for these costs.**

## WHERE ARE CLINICAL TRIALS HELD? WILL I HAVE TO STAY IN A HOSPITAL?

Traditionally, clinical trials have been held at hospitals and other healthcare facilities, with participants visiting on a regular basis to receive treatment and have their vital signs monitored. For most study participants, an overnight hospital stay is not necessary.

**What's more, the rise of technology such as telemedicine and remote monitoring has led to the emergence of new forms of clinical trials, in which participants only make occasional visits to the trial site. Instead, in some cases, treatment and monitoring an occur in the participant's home.**

## WILL I HAVE TO GIVE UP MY CURRENT TREATMENT TO BE IN A CLINICAL TRIAL?

Not necessarily. Depending on the design of the study, you may continue to receive your current treatment. In some cases, currently receiving a certain type of medication can exclude you from qualifying for a trial. A Massive Bio nurse oncologist can help you understand what treatments you may receive if you enroll in a clinical trial.

## WHAT IF I CHANGE MY MIND ABOUT BEING IN A CLINICAL TRIAL?

You are under no obligation to continue in a clinical trial if you decide for any reason that you no longer want to participate.

# WHY ARE CANCER CLINICAL TRIALS IMPORTANT?

Clinical trials are necessary to ensure that medical treatments offered to patients are safe and effective.

**The current system for conducting clinical trials was established in the United States in the early 1960s, after several unsafe drugs that were not adequately tested reached the market, harming and even killing some patients who used them.**

Requiring pharmaceutical products and other forms of medicine to pass through a series of clinical trials before becoming available to all patients helps ensure that they receive treatments with the strongest possibility of offering a benefit, without significant risk.

**Requiring the makers of new medications to rigorously test them before seeking approval from the FDA can also be credited with helping to usher in a new era of oncology therapies that have greatly benefited patients. In the mid-1970s, only about half of all people diagnosed with cancer were still alive five years later.**

Today, that figure has soared, as more than two-thirds of people with cancer reach the five-year survival threshold. And a major reason more people survive cancer today is the availability of new, cutting-edge cancer therapies developed in labs and tested in clinical trials.

# "What Are **Clinical Trials?**"

*by Dr. Arturo LoAlza-Bonilla*

CMO & Co-founder of MassiveBio

# Massive Bio Pioneers Clinical Trial Recruitment Innovation with Strategic Support from Evernorth Health, Inc.

**Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven Technologies Massive Bio, a trailblazing entity in the realm of digital health technology, proudly announces a pivotal advancement in clinical trial recruitment, fortified by a strategic relationship with Evernorth Health, Inc (ENI).**

This groundbreaking collaboration is poised to redefine the clinical trial landscape, seamlessly integrating innovative AI and personalized concierge services to optimize patient-centric recruitment processes and expand access to advanced care.

## Strategic Synergy for Clinical Trials:

Massive Bio's unwavering dedication to revolutionizing clinical trial recruitment is accentuated by its strategic alignment with Evernorth Health, Inc.

This synergy empowers Massive Bio to increase awareness for a myriad of cancer trials, deploying state-of-the-art AI algorithms to proficiently identify potential subjects, healthcare providers, and pharmacies, thereby delivering a seamless and enriched recruitment experience under a value-based and pathway-oriented framework.

## CEO's Statement:

"Our endeavor to radically revamp the clinical trial recruitment landscape and democratize access to advanced care is substantially bolstered through our relationship with Evernorth Health, Inc.," stated Selin Kurnaz, CEO of Massive Bio. "This collaboration intertwines advanced AI and concierge services, propelling us to expedite life-saving research and ensure wider trial accessibility and enhanced patient outcomes."

## Enhanced Patient Outcomes and Access:

Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Massive Bio, emphasized the commitment to swiftly and efficiently connecting patients with suitable clinical trials: "By amalgamating our advanced, AI-driven technologies with extensive resources, we are poised to streamline clinical trial recruitment, offering swift access to innovative treatments and fostering the acceleration of medical research."

# **TRIALBEE** and **MASSIVE BIO** Join Forces to Improve Clinical Trial Access and Patient Recruitment for Oncology and Hematology

**Trialbee, your global patient recruitment and enrollment solution, today announced its Omnichannel Network partnership with Massive Bio, a global leader in AI enabled patient journey mapping platform, to help better connect cancer patients and their oncologists/hematologists to clinical trials.**

Visit Massive Bio at the Trialbee exhibit booth (#1209) at the SCOPE Summit on Feb 11-14, in Orlando, FL to the collaboration and how it improves awareness and recruitment for oncology and hematology clinical trials.

**According to the U.S. Commission on Cancer, only 6.3% of patients participate in clinical research for cancer treatments, which makes it imperative to raise awareness of research opportunities as a care option.**

Trialbee and Massive Bio understand that patients have so much going on in their lives and with their care, that clinical research isn't typically top of mind for them, their families, or even their oncologists – while others may lack the time or knowledge of where to look, or the questions to ask.

**Because many of these trials potentially represent the latest and most innovative methods to save lives, improving the outlook**

**for generations to come, the companies are committed to working together to act now.**

"Our mission at Massive Bio is to raise awareness with our global patient and provider contact centers, physician-to-physician referrals, and mega channel partnerships with a specific focus on oncology and hematology studies," said Selin Kurnaz, PhD, CEO of Massive Bio.

**"We aggregate all of these direct and indirect pathways while providing services for medical records collection, molecular diagnostics testing results collection (aka NGS testing), master pre-screening, and last-mile support (referral, logistics and financial) to make it easier for cancer patients to participate.**

This partnership with Trialbee brings another channel of identification and outreach with hyper-targeted digital recruitment so we can reach more patients together – including those at community-based practices, which was the founding reason of Massive Bio, so we can improve health equity and access for all."

**Trialbee and Massive Bio share similar approaches to recruitment for cancer trials with an emphasis on patient-centered research coupled with total transparency to ensure sites have the information they need to follow-up with interested study candidates.**

"Complex patient recruitment challenges require a thoughtful strategy and, frankly, a new approach," said Matt Walz, CEO of Trialbee. "We have built our Omnichannel Network to expand the reach of our own data-driving recruitment methods without sacrificing our core principles of being highly targeted in our outreach.

**Massive Bio is a perfect example of a valuable partnership that will open new pathways for patients while still remaining hyper-focused on the ideal participant personae for each clinical trial.**

We are impressed by the team at Massive Bio, and we are proud to collaborate with them to raise awareness of clinical trial opportunities for more, and more diverse, patients and families worldwide."

**“It’s often said that finding patients with cancer to participate in a particular trial is like finding a needle in the haystack – so we’re bringing our best and biggest pitchforks,” said Maggie Adamski, Senior Director of Omnichannel Solutions at Trialbee.**

“With our shared mission, Massive Bio helps us reach more patients than ever. We realize one recruitment channel isn’t enough on its own. That’s why we have built our Omnichannel Network with partnerships like this so more patients can discover the possibilities of clinical research as a care option.”

Interested participants will be tracked and managed all within the Trialbee Honey Platform™, which centralizes and standardizes recruitment and enrollment data from all sources to provide unprecedented transparency into the process while reducing burden on sites.

**To learn more about how Trialbee and Massive Bio are working together to improve clinical research access for patients with cancer, visit www.trialbee.com and www.massivebio.com.**

# EXPLORE ALL TREATMENT OPTIONS

available to treat your advanced **multiple myeloma**

Cancer treatment finder

# **Precision Cancer Consortium** Teams with **Massive Bio** to Improve Clinical Trial Matching

Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools.

**PCC was established in 2022 with a shared vision of enabling access to comprehensive testing for all cancer patients globally, and is currently comprised of Roche/Genentech, Novartis, GSK, Bayer, Eli Lilly & Company, Johnson & Johnson/Janssen and AstraZeneca. The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio's Deep Learning Clinical Trial Matching System (DLCTMS). This will optimize the quality and efficiency of matching patients to trials across sponsor programs and improve patient access to targeted Next Generation Sequencing (NGS) testing and tailored interventions.**

Selin Kurnaz PhD, Founder and CEO of Massive Bio, commented, "We are thrilled to be working with the Precision Cancer Consortium to advance precision oncology through our innovative AI analytics tools. With this partnership, we can streamline the process of clinical trial matching and reduce the burden on patients and healthcare systems."

**The PCC is a collaborative initiative to make data-driven precision oncology the new normal for all cancer patients globally, focusing on increasing patient access to targeted NGS testing and tailored interventions. The program sponsored by PCC will generate combined data and insights to optimize the allocation of patients to available ("local") clinical trials based on NGS testing or Comprehensive Genomic Profiling, clinical and patient characteristics, and relevant trial eligibility criteria.**

Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer of Massive Bio, said, "We are proud to partner with the Precision Cancer

## Precision Cancer Consortium Members

Roche | AstraZeneca | BAYER | GSK

janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson | Lilly | NOVARTIS

Consortium and bring our AI analytics tools to the forefront of precision oncology. Our technology utilizes genomics and clinical data from various platforms to present available intervention options for each patient in order to optimize clinical trial matching by reducing inefficiencies and multiple screenings. Together, we can help more patients access the right treatment options and improve outcomes."

**Through this partnership, Massive Bio will design and pilot a trial matching tool for prospectively matching patients through genomic testing and clinical data to a set of selected ongoing biomarker-driven clinical trials within previously defined locations (i.e. site, Health Care Organization, country). The companies will also explore considerations for larger scale or real-world application for further development.**

Yinghui Zhou PhD, PCC Project Lead and Sr. Director, Bayer Translational Sciences Oncology, added, "This collaboration has the potential to address a major challenge in precision oncology and improve patient outcomes. By working together and utilizing a collection of genomics data from multiple sources centralized with the assistance of AI, we can create a valuable scientific resource and optimize the efficiency of clinical trial matching globally and scale."

**About Precision Cancer Consortium (PCC)**
The Precision Cancer Consortium is composed of pharmaceutical and biotechnology companies focused on fostering collaboration on issues and opportunities related to precision oncology with the goal of improving patient outcomes by increasing cancer patient access to comprehensive genomic testing, including next generation sequencing, and addressing major gaps in precision diagnostics availability. For more information, visit the PCC website at

**https://www.precisioncancerconsortium.com/**

PRECISION
CANCER
CONSORTIUM

# MASSIVE BIO'S EXPANDING NETWORK: REVOLUTIONIZING CANCER CARE IN THE US AND BEYOND

**In the ever-evolving world of healthcare, one company stands out for its dedication to revolutionizing cancer care: Massive Bio. As we usher in 2024, Massive Bio proudly celebrates its remarkable achievements and unveils its ambitious vision for the future, promising to transform the landscape of cancer treatment and clinical trials globally.**

**Massive Bio's Mission:** A Beacon of Hope for Cancer Patients Massive Bio's core belief is that every individual, regardless of their geographical location or financial status, should have equal access to cutting-edge therapies and emerging clinical trials. This conviction led to the creation of Massive Bio, a central hub that seamlessly connects patients with the most suitable treatments and clinical trials, ensuring world-class healthcare options are within reach of everyone.

**Triumphant Achievements and Expanding Influence Massive Bio's recent accomplishments are a testament to its commitment and efficacy. The company has achieved a significant increase in clinical trials, now overseeing 78 ongoing projects, up from 50 in the previous year. This growth is paralleled by the expansion of their customer base, now partnering with 29 prestigious pharmaceutical companies.**

In the realm of pharmaceutical commercial products, Massive Bio's innovative solutions have revolutionized patient identification processes, contributing significantly to the success of these products.

**The company's influence extends to collaborations with six of the top ten Contract Research Organizations (CROs), cementing its role as a leader in the industry.**

Massive Bio's network is extensive, encompassing collaborations with 275 patient advocacy groups, 2,850 referring physicians, 30 hospitals, and 30 strategic partners. This network plays a crucial role in broadening the company's outreach and impact in the field of cancer care.

**Vision for 2024:** Expanding Horizons and Transforming Lives Looking ahead, Massive Bio has set its sights on even more ambitious goals.

**The company aims to enroll 250,000 cancer patients in its program by 2024, offering them new hope and access to advanced care options. Furthermore, Massive Bio intends to increase its clinical trial count to 200, enhancing its research and treatment capabilities.**

A key focus for the upcoming year is to expand globally, with plans to establish a presence in 14 countries across Europe, LATAM, and Asia. This expansion reflects Massive Bio's commitment to making a global impact in the fight against cancer.

**In addition to these goals, Massive Bio is excited to announce the forthcoming launch of a groundbreaking product that promises to transform patient pre-screening in cancer care. This innovation is a step forward in the company's continuous effort to refine and elevate the standards of healthcare.**

A Year of Transformation and Impact As 2024 unfolds, Massive Bio remains steadfast in its mission to extend its reach and impact in cancer care. The company's journey, marked by significant achievements, is a source of inspiration and a beacon of hope for cancer patients worldwide.

**Massive Bio extends its heartfelt gratitude to its dedicated team and values the partnerships and collaborations that have been instrumental in its success. Together, they are set to continue making significant strides in healthcare innovation, revolutionizing cancer care and making a lasting impact on the healthcare ecosystem.**

In conclusion, Massive Bio's story in 2024 is not just one of sustained progress, but also a narrative of transformative contributions to healthcare.

**This year is poised to be a pivotal chapter in their journey, echoing their commitment to revolutionize cancer care and positively impact countless lives.**

# MASSIVE BIO CLINICAL NETWORK:
## A Revolutionary Platform for Streamlining Patient Referrals for Clinical Trials

**Setting the pace in precision oncology solutions, Massive Bio proudly announces the introduction of "Massive Bio Clinical Network", a state-of-the-art physician portal designed exclusively for oncologists and heme-oncologists. This monumental development promises to transform the patient referral process for clinical trials.**

Massive Bio Clinical Network serves as an innovative tool enabling physicians to effortlessly screen, monitor and refer patients for clinical trials within the Massive Bio ecosystem. Prioritizing clinical trial inclusion and exclusion criteria, the portal provides accurate eligibility assessment, efficient pre-screening, and easy monitoring of patient referrals.

**Cagatay Culcuoglu**
GM, COO, CTO

In a recent statement about the launch, Cagatay Culcuoglu, Co-founder and Chief Technology Officer of Massive Bio, shared his insights: "Clinical trials are the bedrock of advancements in precision oncology. With the Massive Bio Clinical Network, we aim to bridge the gap between cutting-edge research and patients who can benefit most from it. This platform stands as a testament to our vision: a world where every patient, regardless of where they are, has equitable access to the best treatments and trials. In every feature of this network, we see the reflection of our commitment to physicians, partners, and most importantly patients."Massive Bio is steadfast in its mission to foster a more efficient and precise approach to cancer treatment through its Clinical Network, serving both oncologists and heme-oncologists across the globe. Currently, the network comprises a robust group of 18,191 physicians in the US and 4,587 physicians in Europe, facilitating seamless and streamlined clinical trial referrals and enhancing patient outcomes through its innovative platform.

Over the next 12 months, Massive Bio envisions a significant expansion, with plans to onboard an additional 50,000 physicians internationally.

Massive Bio is leveraging the power of Artificial Intelligence (AI) in its new Clinical Network, transforming the patient referral process for clinical trials.

The platform uses AI to swiftly and accurately match patients with appropriate trials, a step that is fundamental in advancing precision oncology. By optimizing clinical trial matches through real-time data analysis, it promises to usher in a new era of efficient and patient-centered care, offering hope for better outcomes in cancer treatment.

### Key Features of the Massive Bio Clinical Network include:

• Streamlined Patient Management: With its intuitive interface, physicians can easily access patient data, evaluate clinical trial eligibility based on specific criteria, and leverage user-friendly dashboards for optimized patient care.

• Advanced Patient Tracker: Embedded with data analysis tools, this feature allows real-time tracking and assessment of patients throughout the clinical trial referral process, equipping physicians with critical insights for decision-making.

• Efficient Trial Management: The portal simplifies assessment of clinical trial protocols, enabling physicians to review detailed criteria and efficiently pre-screen patients to ensure both trial eligibility and patient safety.

• Seamless Communications: Facilitating effective communication, the platform integrates flawlessly with Massive Bio's CRM system, updating physicians on patient progress and automating notifications about clinical trial enrollment.

• Anonymity and Patient Safety: Patient confidentiality remains uncompromised as the platform utilizes only de-identified patient data, adhering to GDPR and HIPAA regulations and data security standards.

• Enhanced Partner/Account Manager Integration: Partners and account managers can now refer patients for clinical trials on behalf of physicians, promoting seamless collaboration and maximizing patient enrollment.

• Comprehensive Trial and Site Information: Physicians receive easy access to detailed trial and site data, giving them with the knowledge to make informed choices and enhance their patient's experience.

The launch of Massive Bio Clinical Network underscores our unwavering commitment to accelerating clinical trials and the advancement of groundbreaking cancer therapies. With this platform, Massive Bio is poised to redefine clinical trial patient referrals, shaping the future of innovative precision oncology therapeutics and improved patient outcomes.



**Oz Huner** CPO

"Our vision is that all patients should have equal access to new and emerging therapies, regardless of where they live or their ability to pay. Unfortunately, today there's a lot friction for physicians to find the right clinical trial for their patients. That's why we developed Massive Bio Clinical Network, which makes it easy for physicians to screen and refer their patients to cutting edge clinical trials." says Oz Huner, Chief Product Officer of Massive Bio.

For a deeper understanding of the Massive Bio Clinical Network and the vast array of personalized oncology solutions by Massive Bio, please visit **www.massivebio.com** or connect with Massive Bio directly.

# **Awareness** Calendar

**JANUARY:** Cervical Cancer Awareness Month

**FEBRUARY:**

* National Cancer Prevention Month
* Gallbladder and Bile Duct Cancer Awareness Month
* World Cancer Day (Feb. 4)
* National Donor Day (Feb. 14)
* Rare Disease Day (Feb. 29)

**MARCH:**

* Colorectal Cancer Awareness Month
* Multiple Myeloma Action Month
* National Kidney Cancer Awareness Month
* Lymphedema Awareness Month
* Triple Negative Breast Cancer Day (Mar. 3)
* World Lymphedema Day (Mar. 6)
* Anal Cancer Awareness Day (Mar. 21)

**APRIL:**

* Testicular Cancer Awareness Month
* Esophageal Cancer Awareness Month
* Head and Neck Cancer Awareness Month
* Adolescent and Young Adult Cancer Awareness Week (Apr. 1 - 5)
* Oral, Head, and Neck Cancer Awareness Week (Apr. 16 - 22)

**MAY:**

* Bladder Cancer Awareness Month
* Brain Cancer Awareness Month
* Melanoma and Skin Cancer Awareness Month
* National Cancer Research Month
* World Ovarian Cancer Day (May 8)

**JUNE:**

* National Cancer Survivor Month
* National Cancer Survivor's Day (Jun. 2)
* PTSD Awareness Day (Jun. 27)

# AI finds the right trials for you.

**SYNERGY-AI offers a personalized, hassle-free, evidence-based clinical trial matching service to cancer patients. No one should fight cancer alone.**




Google Play

App Store

SYNERGY-AI Cancer Clinical Trial Finder is a mobile app that uses your cancer type, stage, biomarker status, and other data points to identify clinical trials of cutting-edge treatments, at research sites near you. Contact us about enrolling in a clinical trial and let Massive Bio do the rest.

www.massivebio.com